The growth of export volumes of drugs for medical use produced in Russia is one of the key indicators of the development of the pharmaceutical industry of the Russian Federation for the period up to 2030.
The FSUE Endopharm, subordinate to the Ministry of Industry and Trade of the Russian Federation, is actively developing international cooperation in drugs export, while providing the country with the necessary domestic drugs that meet international criteria of quality, efficacy and safety.
One of the key factors in realizing the export potential of the FSUE Endopharm is the conformity of production and quality of products manufactured by the Enterprise to international standards. Foreign partners are most interested in drugs produced on a full cycle basis, which allows to ensure their high quality and affordability, as well as to promptly respond to increased demand.
On July 26-28, 2023, the production site of the Moscow Endocrine Plant FSUE Endopharm was audited by the Inspectorate for Drugs and Medical Devices of the Ministry of Health of the Republic of Serbia.
The inspectors got acquainted with the organization of the work of the Enterprise production units, high-tech equipment of the workshops and labs, personnel training system, supplier selection and risk management, validation policy and other elements of the pharmaceutical quality system of the FSUE Endopharm, including pharmaceutical development. The aim is the consequent registration of a number of Enterprise's popular drugs in Serbia in the form of sterile solutions in ampoules and vials, single-dose syringes, as well as transdermal patches and transmucosal films.
Conclusion on compliance of the FSUE Endopharm, the manufacturer of drugs, with GMP requirements of the Ministry of Health of the Republic of Serbia will be issued in August 2023.
Cooperation in the export of drugs in demand in the Republic of Serbia from the FSUE Endopharm’s range developed following the results of the Healthy Society Forum, organized in March 2023 by the Roscongress Foundation project “Healthy Society” and the Ministry of Health of the Russian Federation, and the subsequent working visit of the Enterprise management to the Republic of Serbia in May 2023.
The Enterprise exports its manufactured drugs to 15 countries. The main foreign consumers of the FSUE Endopharm products are the EAEU, CIS and the Middle East countries. Negotiations are underway to expand the sales market with partners from Africa and Southeast Asia.
According to the results of the first half of 2023, the export indicators of the FSUE Endopharm reached the highest value for the previous 5 years: the increase compared to 2018 was 50%. Export sales in monetary terms showed an increase of 3.5 times in the first half of 2023 compared to the same period in 2022. The share of exports in the total sales pattern increased by 5% compared to the same period last year — up to 7.9%.
It should be noted that the staff is of key importance in the development of the Enterprise, including areas of export. The influx of young, proactive, well-trained specialists, combined with the professionalism of experienced workers, allows to intensify the processes of developing and implementing new products, flexibly adapting work to the needs of the healthcare system of Russia and foreign countries.
These indicators are the result of teamwork and selfless efforts of each employee of the departments of science and pharmaceutical development, implementation and registration of medicines, production, quality assurance and control, legal and financial units, procurement and logistics, department of foreign economic activity.
In 2023-2026, the main growth points of export sales will be the expansion of the geographical directions of export development and the nomenclature of exported drugs, including modern non-invasive forms of centrally-acting analgesics, investments in expanding production capacities, as well as informing representatives of foreign professional medical and business communities about the products and new developments of the FSUE Endopharm by participating in exhibitions and congress events.
Comment type is not specified in the component properties.